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Abstract: Uveal melanoma (UM) is the most common primary intraocular tumour in adults, with a 
mean survival of six months following metastasis. The survival rates have not improved in over 30 
years. This study has shown that sister chromatid exchange (SCE) is low in UM which is likely due 
to a reduced expression of FANCD2. As FANCD2 can function to suppress non-homologous end 
joining (NHEJ), this study therefore investigated NHEJ in UM. The activation of the catalytic subunit 
of the NHEJ pathway protein DNA-dependent protein kinase (DNA-PK) was measured by 
analysing the foci formation and the ligation efficiency by NHEJ determined using a plasmid-based 
end-joining assay. Using small-interfering RNA (siRNA) knock-down, and chemical inhibitors of 
DNA-PK, the survival of primary UM cultures and two cell lines were determined. To assess the 
homologous recombination capacity in response to the inhibition of DNA-PK, a SCE analysis was 
performed. In addition, to support the findings, the messenger RNA (mRNA) expression of genes 
associated with NHEJ was analysed using the Cancer Genome Atlas (TCGA)-UM RNAseq data (n 
= 79). The NHEJ activity and DNA-PKcs activation was upregulated in UM and the inhibition of 
DNA-PK selectively induced apoptosis and sensitized to ionising radiation and inter-strand cross-
linking agents. The inhibition of the NHEJ protein DNA-PK is lethal to UM, indicating a potentially 
effective therapeutic option, either alone or as a sensitizer for other treatments. 
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1. Introduction 
Uveal melanoma (UM) is a rare but an aggressive tumour of the eye that annually affects 57 
adults per million in Caucasian populations, with mortality rates of approximately 4050% within 
ten years of diagnosis [13]. The primary UM are effectively treated by surgery or radiotherapy. 
However metastatic UM is highly resistant to chemotherapeutic agents, limiting clinical treatment 
strategies [4]. Although the incidence of metastases at presentation is low, they subsequently develop 
with a peak incidence approximately three to five years after treatment of the primary tumour, 
underlining the importance of developing new and effective treatments to target this disseminated 
disease [57]. 
Non-random aberrations of chromosomes 1, 3, 6 and 8 are classically found in UM and are 
commonly used as reliable prognostic indicators [810], but these are mainly associated with the 
progression rather than initiation of UM [11,12]. In contrast, mutations in guanine nucleotide binding 
proteins GNAQ and GNA11, although not prognostic, occur in approximately 8090% of UM and are 
considered an early, if not initiating event in UM [1316]. These mutations produce constitutive 
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activation of the ERK 1/2 / MEK and Yes Associated Protein (YAP) [17]. In cutaneous melanoma (CM), 
the targeted MEK inhibitor therapies are effective but, surprisingly they have shown little value in 
UM [18]. In addition, UM are resistant to other chemotherapy agents successful in the treatment of 
CM, notably the DNA inter-strand cross-linking (ICL) agent mitomycin-C (MMC). MMC prevents 
DNA replication by forming cross-links in DNA and is valuable as a treatment for a range of solid 
tumours, including conjunctival melanoma [19,20]. The single agent use of MMC is not however 
effective for most UM, possibly as previously shown, due to the deficient cytochrome-P450-mediated 
drug metabolism [21]. 
Therapies, such as ionising radiation (IR) and MMC, work by inducing DNA damage. A cells 
DNA damage response (DDR) involves a complex interplay of pathways designed to recognise and 
repair lesions occurring during normal cellular processes and those induced by agents, such as MMC. 
The double strand breaks (DSBs) arising either directly, or as a failure of single strand break repair, 
are the most lethal. The two main pathways for DSB repair are homologous recombination (HR) and 
non-homologous end joining (NHEJ). Repair by the latter is more error prone and consequently can 
lead to increased genetic instability. The selection of the pathway for repair depends on many factors, 
including the damaging agent, point in cell cycle and cell type. Furthermore, evidence suggests that 
a competitive relationship between the pathways can exist [22,23]. 
The authors have previously shown that low sister chromatid exchange (LSCE) frequency and 
elevated ·H2AX foci formation are a feature of UM cell lines and primary short-term cultures (STCs), 
indicating that an irregularity in DSB repair exists in UM [24]. Furthermore, low RAD51 foci 
formation suggested low levels of endogenous HR in UM due to the low expression of Fanconi 
Anemia complementation group D2 (FANCD2) [25]. Given the relationship between HR and NHEJ 
during DSB repair, and the finding that FANCD2 suppresses NHEJ [26], this study investigated 
whether UM have increased basal activity of the alternate DSB repair mechanism NHEJ, and whether 
its inhibition may represent a promising treatment option for UM. 
2. Results 
2.1. NHEJ is Elevated in UM 
NHEJ in UM was first investigated by analysing the activation of DNA-PK measuring the foci 
formation of phosphorylated DNA-PKcs at the Serine 2056 (Ser2056) residue, an event that initiates 
NHEJ following DNA damage [27]. In this study, the spontaneous foci formation of Ser2056 DNA-
PKcs was significantly higher in both UM cell lines and UM STCs when compared to the control cell 
lines, WM793 and MRC5VA (P < 0.01) (Figure.1). Furthermore, the ligation efficiency of NHEJ, 
estimated using a blunt-end cut plasmid transfection assay, demonstrated that DSB ligation efficiency 
was higher in both UM cell lines compared with the controls (Figure 1). Ligation efficiency in all cell 
lines was inhibited with 10 µM treatment of DNA-PK-inhibitor NU7026, confirming that the assay 
was effective in measuring end joining. 
 
Figure 1. Non-homologous end joining (NHEJ) is elevated in uveal melanoma (UM) cell lines and 
short-term cultures (STCs). (A) UM cell lines and STCs showed greater formation of spontaneously 
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activated serine 2056 DNA-PK foci compared to the control cells (**P < 0.01). The error bars represent 
the standard error from three independent trials. (B) Representative microscope images of cell lines 
stained for phosphorylated DNA-PKcs foci and counterstained with DAPI. The scale bar represents 
5 microns. (C) NHEJ capacity assessed by the end-joining efficiency assay. If the plasmid had been re-
ligated then colonies successfully formed. The end-joining efficiency (% ligation efficiency) was 
significantly elevated in UM cell lines compared with the control cell lines WM793 and MRC5VA (*P 
= <0.05). The end-joining capacity was eliminated in all cells treated with 10 µM NU7026 DNA-PK 
inhibitor, confirming the validity of the assay for measuring NHEJ-mediated ligation. 
The mRNA expression of genes associated with DNA repair pathways was analysed using the 
Cancer Genome Atlas (TCGA)-UVM RNAseq data (n = 79). For all UM, NHEJ pathway genes, DNA-
PKcs (alias PRKDC), XRCC5 and XRCC6, were significantly highly expressed compared to DSB-HR 
pathway genes ATM, ATR, FANCD2, BRCA1, BRCA2 and RAD51 (P < 0.0001) (Figure 2). It is, 
however, of interest that LIG4 is not equally upregulated, and a recent study has also highlighted the 
upregulation of PRKDC but not LIG4 [28]. 
 
Figure 2. Confirmatory expression of NHEJ pathway genes in the Cancer Genome Atlas (TCGA). 
TCGA UM (n = 79) mRNA expression of genes involved in DNA repair pathways (n = 10). When 
compared to DSB-HR pathway genes ATM, ATR, FANCD2, BRCA1, BRCA2 and RAD51, NHEJ 
pathway genes PRKDC (Alias DNA-PKcs), XRCC5 and XRCC6 were significantly highly expressed in 
UM (Tukey's multiple comparisons test ****Adjusted P value <0.0001). BAP1 expression is normalized 
across both D3 and M3 UM, which accounts for the comparative upregulation. 
The KaplanMeier survival plot was generated with respect to monosomy 3, a gain of 8q 
(M3G8q) and disomy 3 (D3) (Figure S1). As previously reported, M3G8q was associated with reduced 
survival (P <0.0001) and DNA-PK was found to be highly expressed in the cohort of M3G8q compared 
to D3 (P <0.0001) (Figure S1). Of note, the survival plots for the copy number deletion of BAP1 
(location 3p) and the amplification of DNA-PK / PRKDC (location 8q) matched exactly the plots for 
survival of M3G8q. The transcripts per million (TPM) value, however, for DNA-PK / PRKDC 
correlated to the copy number of 8q (Figure S2) offering an explanation for the association between 
the increased expression of DNA-PK / PRKDC with M3G8q. As the expression for all genes were 
normalized across both D3 and M3 UM. In combination with the experimental data (Figure 1), these 
findings demonstrate that NHEJ, from initiation through to completion, is upregulated in UM. 
2.2. Inhibition of DNA-PK Mediated NHEJ is Toxic to UM and Induces Apoptosis 
All UM showed increased sensitivity to the DNA-PK inhibitor NU7026 when compared with 
the control cell lines WM793, melanocyte progenitor cell line LA1-5s and a series of sarcoma cell lines 
(A673, SKUT-1, SKLMS-1 and SW1353, grouped to simplify the data) (Figure 3). The 50% lethal dose 
(LD50) was 10 µM in UM cell lines SOM 157D and SOM 196B compared with 2030 µM in controls (P 
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= 0.04 and 0.02, respectively by a Students T-test). At 30 µM UM cell line 196B exhibited a 100-fold 
increased sensitivity versus the controls (P < 0.001 by a Students T-test). Due to the limited material 
available in UM STCs, these were assessed for sensitivity to NU7026 using the MTT assay. All ten 
UM STCs analysed were significantly more sensitive to NU7026 than the control (Figure S3) (P < 0.001 
by a Students T-test). The inhibition of DNA PKcs phosphorylation following the treatment with 
10µM NU7026 for 24 h was confirmed using a western blot analysis (Figure 3). Both UM cell lines 
were resistant to PARP inhibition in comparison to the HR deficient BRCA1 mutant cell line COV362 
(Figure S4). 
 
Figure 3. The sensitivity of UM cells to inhibition of DNA-PK. (A) UM cell lines SOM 157D and 196B 
were sensitive to DNA-PK inhibitor NU7026 when compared to the cutaneous melanoma (CM) cell 
line WM793, LA1-5s and an array of sarcoma cell lines (**P = <0.001 and *P =<0.05 respectively). (B) 
Inhibition of DNA-PK following treatment with NU7026 was confirmed by western blot in SOM 196B. 
(C) UM cell lines SOM 196B and SOM 157D and five available UM STCs show elevated apoptotic 
response in response to treatment compared to controls (*P = <0.05). (D) siRNA depletion of DNA-
PK induced greater cytotoxicity in UM cell line SOM 196B compared with the control cell lines (**P = 
0.003). Significance is measured against the scrambled siRNA control to account for the cytotoxic 
effects of transfection. Survival in the scrambled siRNA treated cultures was similar across all cell 
lines (P = >0.1). The error bars indicate the standard deviation in three independent trials. (E) DNA-
PK inhibition by siRNA was confirmed by a western blot in the 3 cell lines tested, again using 
scrambled siRNA as the control. 
As persistence of DSBs caused by impaired repair can trigger apoptosis, DNA-PK inhibition 
induced cell death, rather than just impeded growth, was confirmed by the Annexin V-FITC/FACS 
method. The Annexin V positive / PI negative cells in UM and the controls 48 h following the 
treatment with 10 µM NU7026 (the LD50 dose for UM), were significantly higher in the UM cell lines 
and STCs compared to the controls (Figure 3) (P < 0.05 by a Students T-test). As Annexin V positivity 
/ PI negative is not always representative of early apoptosis, additional procedures (e.g., TUNEL) 
would provide further confirmation, but the higher levels in the UM cell lines following inhibition is 
suggestive of increased apoptosis.  
2.3. siRNA-Mediated Depletion of DNA-PKcs is Toxic to UM. 
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Although NU7026 is highly selective against DNA-PK over other phosphatidyl inositol kinases 
(PIKs), it was necessary to determine whether the toxicity was due to specific targeting of DNA-PK 
or another unknown interaction. Therefore, the siRNA-mediated depletion of DNA-PKcs was 
performed. A control treatment of non-targeted scrambled siRNA (s.c.) accounted for the cytotoxic 
effects of transfection. The depletion of DNA-PKcs was highly cytotoxic to the UM cell line, SOM 
196B, compared to both control cell lines, WM793 and MRC5VA (P = 0.003 by a Students T-test; 
Figure 3). The siRNA-mediated depletion of DNAPKcs was confirmed using a western blot analysis 
(Figure 3). The findings for siRNA were similar to those with the chemical inhibitor NU7026, 
confirming toxicity was indeed specific to the disruption of DNA-PK.  
2.4. Confirmation of UM Sensitivity to DNA-PK Inhibition with the Alternative Inhibitor NU7441 
To support DNA-PK inhibition as a therapeutic option in UM, toxicity assays were performed 
using an alternative DNA-PK inhibitor, NU7441 (Figure 4). In pharmacokinetic studies in vivo, this 
compound has been shown to maintain clinically relevant concentrations in tumours significantly 
longer in comparison to NU7026 [29]. The UM cell lines SOM 157D and 196B were significantly more 
sensitive to treatment with NU7441 compared to the MRC5VA cells and WM793 cells (Figure 4). The 
LD50 values for SOM 157D and SOM 196B were 2.2µM and 0.8µM respectively, compared to > 5 µM 
in the control cells (P = 0.0088 and 0.0043 respectively by a Students T test). Additionally, the 
treatment with 2.5 µM NU7441 for 48 hours selectively induces apoptosis as suggested by the increase 
in Annexin V positive / PI negative cells in UM (Figure 4), as opposed to no increase in apoptosis in 
treated control cells MRC5VA and WM793 cells (P <0.05 by a Student T-test).  
 
Figure 4. The sensitivity of the UM cell lines to DNA-PK inhibitor NU7441. (A) The UM cell lines 
SOM 157D and SOM 196B were sensitive to treatment with NU7441 DNA-PK inhibitor compared to 
the control cell lines (** P = 0.0088 and **P = 0.0043 respectively by a Students T test). (B) The 
percentage of apoptotic cells as suggested by Annexin V positivity was significantly increased in the 
UM cell lines SOM 157D and 196B in response to treatment with 2.5 µM NU7441 for 48 h compared 
to controls (* P = <0.05). The error bars indicate the standard deviation in three independent trials. 
2.5. DNA-PK Inhibition Potentiates the Cytotoxic Effects of IR in UM cells and Sensitizes UM to ICL 
Agents 
DNA-PK inhibitors have been shown to be effective in adjuvant therapy strategies in other 
tumours [30], and the findings of this study indicate a similar potential for UM. The DNA-PK 
inhibitor, NU7026 augmented the cytotoxic effects of IR in both the UM and control cell lines (Figure 
S5). At low doses of IR (2Gy) however, SOM 196 was sensitized three to four-fold in comparison to 
the control cell line WM793 (P = 0.002), while at higher doses of IR, there was no significant difference 
between their response, indicating that UM may respond more efficiently to adjuvant therapy 
strategies using DNA-PK inhibitors. 
The potential for DNA-PK inhibitors in combined therapy also extends to previously ineffective 
therapies, including MMC, and in this study, the DNA-PK inhibitor NU7026 also sensitized the UM 
cell line SOM 196B to MMC (P = 0.02 at 20nM by a Students T-test). In comparison, any further 
cytotoxicity in the control cell line WM793 was not significant (P = 0.65) (Figure S5). In addition, most 
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primary UM STCs were also found to be more resistant to MMC compared with the cell line WM793 
(P<0.05 at 50nM), and most were sensitized to MMC with the co-administration of 10 µM NU7026 (P 
<0.05 at 25 nM) (Figure S5). These effects were not restricted to MMC. Cisplatin, another DNA cross-
linking agent, is not cytotoxic in UM, but the co-administration with 10 µM NU7026 increased its 
cytotoxic effects in the UM cell line, SOM 196B (P=0.04 at 2 µM) (data not shown). Given the 
comparable response to cisplatin in the cell line and due to the limited cell numbers obtainable from 
STC of UM, the inclusion of UM STCs were restricted to the MMC investigation. 
2.6. HR Functionality in UM Following Inhibition of NHEJ 
As UM clearly have upregulation of NHEJ, the question arises as to whether LSCE are due to 
HR being outcompeted by NHEJ. An increase in SCE compared to the spontaneous levels was 
observed following treatment with NU7026 (P < 0.05), and the relative increase in SCE levels was 
comparable to that for the similarly treated WM793 line (Table 1). This finding suggests that the HR 
pathway is intrinsically functional in UM, and supports the notion of competition between the HR 
and NHEJ pathways [23,26].  
Table 1. DNA-PK inhibition raises sister chromatid exchange (SCE) levels in UM in a proportional 
manner. 
 Mean SCE/Cell Median SCE/Cell Range 
WM793 + DMSO 13.69 13 919 
WM793 + DNAPKi 29.27 24 1454 
SOM 196B + DMSO 4.25 4 19 
SOM 196 + DNAPKi 6.78 6.25 318 
SOM 157d + DMSO 5.97 6 213 
SOM 157d + DNAPKi 9.97 8 426 
SCE analysis of UM cell lines demonstrates an increase in SCEs observed following treatment with 
10µM NU7026 in both UM cell lines, despite levels of SCE remaining significantly reduced compared 
to spontaneous SCE levels in WM793 cells (*P = <0.05). Approximately 30 cells scored per condition. 
Error bars indicate the standard deviation in three independent trials. 
3. Discussion 
Previously, we found that UM has atypically low levels of SCE compared to both other cancer 
cell lines and normal cells [24]. The formation of SCE is most commonly associated with the HR 
pathway [31]. It would therefore be reasonable to hypothesise that UM is defective in HR, but as UM 
is notoriously resistant to both radiation and DNA-damaging agents (which HR deficient tumours 
are usually highly sensitive to [32]), an upregulation of an alternative DSB repair pathway to HR 
seems more probable. The data presented here, demonstrating the upregulation in vitro of functional 
NHEJ in both UM cell lines and STCs, is supported by gene expression analysis of the TCGA showing 
a significant increase in NHEJ proteins in comparison to HR proteins in 79 UM patients (Figure 2). 
Furthermore, the present study showed that all UM were more sensitive to the inhibition of DNA-
PK and that apoptosis was induced when compared with other normal and cancer cell lines (Figure 
3; Figure 4).  
Although DNA-PK, and therefore perhaps NHEJ, is vital to the survival of UM they are 
seemingly not intrinsically incapable of HR. A functional HR pathway in UM is indicated by the 
resistance to PARP inhibition and the increase in the observed levels of SCE following the inhibition 
of DNA-PK (Table 1, Figure S2). Although still lower than the control WM793 cells, the relative 
magnitude for the increase of SCE in UM was comparable to that of the control line (an effective 
doubling of all lines) suggesting that in all instances following the inhibition of DNA-PK, HR was 
prompted. 
UM are not alone in having LSCE, as a reduced SCE formation has also been reported in Fanconi 
anaemia (FA) pathway deficient cells compared to proficient cells [33]. It has previously been shown 
that UM is deficient in the FANCD2 protein associated with the FA pathway [25], and as one of the 
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suggested roles of FANCD2 is to inhibit NHEJ [26,34], its depletion in UM could therefore account 
for both the observed LSCE and overexpression of NHEJ. FANCD2 has also previously been shown 
to influence HR and our previous data in UM supports this by demonstrating a reduction in 
spontaneous RAD51 foci [25]. It is important to note that reduced HR, due to increased NHEJ, may 
have different consequences to where there is a fundamental inability to carry out HR, as for example 
is seen in BRCA deficient cells, since heterozygous carriers of BRCA2 germline mutations exhibit 
increased spontaneous SCE despite impaired HR [35].  
If UM are dedicated to NHEJ and equally committed to functional DNA-PKcs, an interesting 
therapeutic window is opened, as the cells deficient in DNA-PKcs have been shown to display 
heightened sensitivity to DSB-inducing agents [36]. In reverse, the over-expression of DNA-PK has 
been associated with increased chemo- and radio-resistance [37,38], potentially explaining the well 
documented resistance of UM to such therapies. Certainly, this study found that compound NU7026 
sensitized UM cells to IR, MMC and Cisplatin. For UM, plaque radiotherapy achieves comparable 
survival rates to those obtained by enucleation [1], but a more effective response at a lower dose 
(Figure S3) may increase the overall response rates as well as reducing morbidity. Our observation 
that DNA-PK inhibitors sensitized UM to MMC contribute a further mode of ICL resistance to our 
previous finding of poor drug metabolism via altered CYTP450 [21]. Whether these modes are 
independent or share a common mechanism requires further investigation and may reflect 
heterogeneity with individual UM. 
A potential competitive relationship between HR and NHEJ is proposed for other cancers 
[22,23,26] and here, this study shows that it likely exists in UM. This relationship may explain why 
in clinical trials Melphalan has been shown to have some effectiveness against UM [4], as resistance 
to Melphalan requires a fully functional HR capacity and indeed FANCD2 expression [39]. UM, thus 
having a reliance/preference for NHEJ and reduced FANCD2 expression, initially respond to 
Melphalan treatment. The reasons why they relapse later is less clear and it will be important to 
determine whether preferential use of NHEJ continues later in the disease or whether residual HR 
activity is enough to allow resistance to Melphalan. The exact mechanism for preference of UM for 
NHEJ repair is not clear at this point. Recent evidence has begun to suggest a consensus on how UM 
repair DNA damage with studies showing as the authors have, that Olaporib is not efficient alone on 
UM [40] and that PRKDC is upregulated, with NU7026 being an effective regulator of UM 
proliferation [28]. There are many points to explore in future studies. The use of assays, such as the 
DR-GFP/EJ5 assay, are required to investigate rigorously the HR status, whilst the anomaly of 
reduced LIG4 expression may shed light on the interplay between HR and NHEJ in UM. Further 
investigations will provide a better understanding of the conundrum of selection for preferential DSB 
repair by UM and may provide new answers for the treatment of this difficult to treat melanoma. 
4. Materials and Methods  
4.1. Cell Culture 
Two UM cell lines (Sheffield Ocular Melanoma, SOM 157D and SOM 196B) and short-term 
cultures (STC) of UM (SOM 561-572) were established from primary posterior UM biopsies from 
patients receiving surgical treatment at the Royal Hallamshire Hospital, Sheffield, UK, as described 
previously [41]. The clinico-pathological details of the STCs are provided in Table S1. The informed 
consent from all patients was obtained with ethical approval (SSREC 94/247 and 09/H1008/141) and 
the project followed the tenets of the Declaration of Helsinki. The cell lines and STCs were maintained 
as previously described [41]. In addition, the controls used were the CM cell line WM793 (a gift from 
Dr. M Herlyn, Wistar Institute, Philadelphia, USA), sarcoma cell lines SKUT-1, SKLMS-1, SW1353 
and A673, fibroblast cell line MRC5VA, melanocyte progenitor cell line LA1-5s and BRCA-deficient 
ovarian cancer cell line COV362 (all ATCC). The MRC5VA cell line was chosen as the normal 
comparison for most studies since the growth of LA1-5s was more variable in the standard medium 
used for all lines. The STC of UM, because of their nature and insufficient cell numbers, were used 
only where possible to support the findings on the UM cell lines. 
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4.2. DNA Repair Protein Foci Formation Analysis 
To measure the initiation of NHEJ repair, the cells were analysed for foci formation of 
phosphorylated DNA-dependent protein kinase (DNA-PK) (S2056, Abcam; 1:500 dilution) as 
previously described [24]. The percentage of the cells exhibiting greater than 5 foci per cell was 
calculated. 
4.3. End-Joining Efficiency Assay 
To measure ligation efficiency of DSBs in the cell lines, 5 × 106 exponentially growing cells were 
electroporated with 100 ng of agarose gel-purified whole or Sal-I cut pUC19 plasmid (New England 
Biolabs, Hertfordshire, UK) in separate flasks and incubated for 48 h. The DNA was extracted using 
the Qiagen (Sussex, UK) mini-prep plasmid kit according to the manufacturers instructions and 
measured on a nano-drop spectrophotometer. Further, 100 ng of extracted DNA from each test was 
then separately transfected into competent TOP-10 E. coli cultures (Qiagen) on ice followed by 20 s in 
a 42 °C water bath, then 30 min on ice. The cultures were grown in SOB bacterial medium for 1 h at 
37 °C with shaking at 225 rpm, then plated at various densities onto SOB-agar plates with 100 µg/mL 
ampicillin for each test. The transfection efficiency of the E. coli culture was calculated from the 
number of colonies resulting from a control transfection of agarose gel-purified whole pUC19 
(equations given below). The colony counts from each cell line test were then converted into µg DNA 
in the extract using this transfection efficiency according to Qiagens guidelines. The ligation 
efficiency for each cell line was calculated as the fraction of total DNA in the Sal-I cut plasmid extract 
versus the whole plasmid extract. Additionally, a small volume of untransfected E. coli cells was 
plated onto ampicillin-free agar plates to control for contamination. The equations for calculating 
transfection efficiency: 
Transformation efficiency per µg DNA of the TOP10 E. coli =  
(number of colonies / µg DNA) x (total transformation volume / volume plated) 
µg DNA per mammalian cell line extract = 
[(number of colonies) × (total transformation volume/volume plated)] / Transformation efficiency per 
µg DNA of the TOP10 E. coli 
4.4. The Cancer Genome Atlas (TCGA) UM Omics Data Analysis for Upregulation of NHEJ 
The primary clinical data of UM was downloaded from the TCGA database 
(http://gdac.broadinstitute.org/) as well as from two published supplementary datasets on 19 
December, 2018 [42,43]. The RNAseq (transcripts per million (TPM) values, log2(x+0.001) 
transformed) and the copy number (gene-level gistic2 thresholded) data of UM were downloaded 
from the UCSC Xena TCGA Pan-Cancer Atlas Hub on 4 January, 2019 [44]. The UM samples were 
classified into two cohorts: Monosomy 3 chromosome 8q gain (M3G8q, N = 47) and Disomy 3 (D3, N 
= 32). The KaplanMeier estimator was used to determine the relationship among the cytogenetic 
abnormalities and patient survival. The statistical significance of the survival plots was evaluated 
using the log-rank (Mantel-Cox) test. The violin plot was used to visualize the distributions of the 
gene level normalized counts, and the statistical significance of the violin plots was evaluated using 
the unpaired t-test or Tukey's multiple comparisons test. The values of P < 0.05 were considered 
significant.  
4.5. Toxicity Assays 
Clonogenic survival assays: For measurement of sensitivity to DNA damaging agents, 
clonogenic survival assays were performed as previously described [21]. The incremental 
concentrations of the DNA-PK inhibitors (NU7026 Calbiochem (MERCK) Feltham UK and NU7441 
Selleckchem Houston USA, and Poly(ADP-ribose) polymerases (PARP) inhibitor (Olaparib 
Calbiochem) were used. The alkylating agent mitomycin C (MMC) (Sigma Aldrich, Poole, UK) and 
the crosslinking agent cisplatin (Sigma Aldrich) were also tested and in all instances, the lines were 
cultured for 14 days. For tests using drugs dissolved in DMSO, all plates were treated with equal 
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volumes of DMSO to control for toxicity caused by the solvent. The exposure to IR was achieved 
using a CIS IBL 437 Cesium-137 irradiator. For sensitization studies, the cells were treated with 
inhibitors for 2 hours prior to the damaging agent. MTT survival assays: As the clonogenic assay 
require an optimum number of cells for visualisation of the colonies, the slower growth rate of most 
STCs of primary UM were less amenable to this assay. Therefore, STCs from the primary UM were 
assayed by MTT as previously described [21]. For clonogenic assays, the survival fractions were 
calculated as the proportion of the cell colonies formed in the treated plates compared to the 
untreated control plate, and the average survival fractions were obtained. For the MTT assay, 
absorbance was measured at 570nm and for both assays, the controls were the relevant blank, either 
media or DMSO in media, depending on the solubility of the drug. 
4.6. Protein Expression by Western Blotting 
The protein expression of phosphorylated DNA-PK catalytic subunit (DNA-PKcs) and the total 
DNA-PK, SDS-PAGE and western blotting were performed on exponentially growing cell lines as 
previously described [21] using antibodies to DNA-PK (rabbit anti-human, Santa Cruz 
Biotechnologies) and phosphorylated DNA-PKcs at Serine 2056 (rabbit anti-human; Abcam, 
Cambridge, UK), each diluted 1:1000 in 5% bovine serum albumin solution.  
4.7. Annexin V Apoptosis Assay 
To measure the apoptotic response to DNA-PK inhibitors, 1 × 106 cells were seeded into 10 cm 
culture dishes and exposed to either 10 µM DNA-PK inhibitor NU7026, 2.5µM NU7441 or DMSO as 
a control and incubated at 37 °C/5% CO2 for 48 h. The cells were harvested and incubated with the 
Annexin V-FITC Fluorescence Activated Cell Sorting (FACS) assay kit (BD Pharmingen, Oxford, UK) 
according to the manufacturers instructions and measured as previously described, gating for 
Annexin V positive and PI negative cells [24]. 
4.8. siRNA Transfection 
The control non-targeted scrambled oligonucleotide and siRNA oligonucleotides designed to 
target DNA-PK were purchased from Eurofins MWG Operon (Ebersberg, Germany). 
(Sense:[GAUCGCACCUUACUCUGUU]-RNA-[TT]-DNA; 
Antisense: [AACAGAUAAGGUGCGAUC]-RNA-[TT]-DNA). 
Further, 10,000 cells grown in 6-well plates overnight were transfected with 70 nM scrambled 
siRNA or 70 nM DNA-PK targeting siRNA using Dharmacon SiPort reagent (Dharmacon, Thermo 
Fisher Scientific, Loughborough, UK) according to the manufacturer's instructions. The cells were 
cultured in a normal growth medium for 48 h before re-plating for the clonogenic toxicity assay. The 
depletion was confirmed by western blotting. 
4.9. Sister Chromatid Exchange Analysis 
Furthermore, 10,000 cells were seeded into 6-well plates and treated with 10 µM NU7026 for 48 
h (or DMSO for control cells). Following 48 h of treatment, the visualisation of SCEs was performed 
as previously described [24]. Approximately 30 cells per treatment group were scored.  
4.10. Statistical Analysis 
The Students t-test or Tukey's multiple comparisons test were applied to the data at a statistical 
significance threshold of 0.05. 
5. Conclusions 
Although this is a preliminary study, and additional functional investigations are required to 
support the findings, UM appear to upregulate NHEJ repair and hence, have a reliance on DNA-PK. 
This reliance seems to be an integral facet of UM, as it was evident in all UM regardless of other 
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genetic changes. DNA-PK inhibitors were thus found to be a universally effective treatment against 
all the UM tested and could sensitize UM to the effects of IR and both MMC and Cisplatin. These 
findings suggest that the DNA-PK inhibitors provide a promising new line of therapy, either as a 
stand-alone agent, or in combination, for what has been previously a highly resistant and difficult to 
treat malignancy. Further studies are however required to support our findings and to establish what 
the HR status of UM is, and why UM seemingly have this apparent reliance on NHEJ. 
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